(561) 802-3060 info@mri-news.com

Eczema Study | Lunch and Learn Event

MRI holds eczema (atopic dermatitis) lunch and learn event.


Our recent Eczema Study | Lunch and Learn event was a great success.  Dr. Thomas Ross, a local dermatologist with over 20 years of experience, shared with our attendees many new and interesting facts about Eczema (Atopic Dermatitis) including its underlying causes, diagnosis and the treatments currently available to ease the skin conditions related to the disease.

Metabolic Research Institute Inc. (“MRI”) is currently recruiting volunteers for a clinical research study evaluating the safety and effectiveness of an investigational topical cream for use by patients aged 12 – 70 who have been diagnosed with mild to moderate eczema (atopic dermatitis).  If you (or someone you know) has been diagnosed with eczema (atopic dermatitis) and is interested in learning more about this study, please call MRI (561) 802-3060 or visit: https://www.metabolic-institute.com/dermatitis/

Oral Insulin Capsule for Type2DM

Clinical Research News

New Clinical Advances: Insulin Delivery Type 2 Diabetes
ORMD 0801 – INVESTIGATIONAL ORAL INSULIN CAPSULE FOR T2DM

Diabetes is a chronic condition characterized by hyperglycemia, or elevated blood glucose levels. If left untreated, diabetes may lead to complications such as cardiovascular disease, chronic renal failure, retinopathy and amputations.

Type 2 diabetes (T2DM) is a progressive disease characterized by impaired ß cell function and insulin resistance. There are over 340 million type 2 diabetics worldwide with an economic burden of close to half a trillion dollars annually.

Orally administered insulin should bring with it enhanced patient compliance. In addition, intestinally absorbed-oral insulin actually mimics insulin’s natural location and gradients in the body by first passing through the liver before entering the bloodstream.

Oramed’s investigational oral insulin (ORMD-0801) has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. (source: https://www.oramed.com/pipeline/ormd-0801-type-2/)

Metabolic Research Institute Inc. (“MRI”) in West Palm Beach, Florida is currently recruiting adult volunteers to participate in this study. For more information, please call Metabolic Research at (561) 802-3060 or visit our website: https://www.metabolic-institute.com/dm2study/

About Metabolic Research Institute Inc.

Metabolic Research Institute, Inc. (“MRI”), is a private Clinical Research Company located at 1515 North Flagler Drive, Suite 440, West Palm Beach Florida 33401. Unless otherwise noted, all study-related appointments for qualified clinical participants in any MRI research trial will take place at this address.

Metabolic Research Institute’s clinical trials are designed to add to medical knowledge related to the treatment and prevention of diseases or conditions, whether it’s diabetes, high blood pressure, heart disease, high cholesterol, or a variety of other health issues.

Endocrinology Update for the Primary Care Practitioner

Free CME Educational Credits Available

 

Endocrinology Update flyerThis symposium will explore new guidelines and provide updates in the management of diabetes, thyroid and other endocrinologic disorders, and will introduce practical approaches to providing optimal patient care in these areas.

Registration is free…reservations required
Saturday September 28, 2019  |   7:00 AM – 5:00 PM

The intended audience for this conference includes primary care physicians and related medical professionals who are seeking to increase their understanding of diabetes, thyroid disease and other endocrine disorders.

Seminar topics to be covered will include:
• Diabetes and CVD • Practical Approaches to Insulin Therapy • Diabetes Technology Update • Hashimoto’s Disease • Osteoporosis • Thyroid Nodules • Obesity Management • Hypogonadism

 

 

Sponsored by Palm Beach Diabetes & Endocrine Specialists, PA
For more information, or to register for this event, go to: https://www.pbdes.com/endocrinology-seminar-2019/

Colorado Law Caps Monthly Insulin Costs at $100 for Insured Patients

Coloriado Governor signs insulin pricing reform

May 23, 2019 at 10:11am

-Craig Idlebrook

Yesterday, Colorado governor Jared Polis signed into law a measure that will cap total monthly insurance co-pays for insulin at $100. All insurers in the state will have to comply with the new regulation by January 1st, 2020.

The measure caps out-of-pocket costs for a 30-day supply of insulin at $100 for Coloradans with insurance. However, it does not provide a similar cap for out-of-pocket insulin costs for those in the state who lack insurance, nor does it cap out-of-pocket costs for other diabetes supplies.

The legislation also requires the Colorado Department of Law to investigate insulin pricing practices by pharmaceutical companies, pharmacy-benefit managers (PBMs), and insurers, and generate a report that will be made available to the public by November 1st, 2020.

The legislation does not block insurers or PBMs from offering monthly insulin copay caps lower than $100. Such a carve-out may prove important in the future, as insurers and PBMs have been under intense political pressure to cap out-of-pocket insulin costs. Recently, Cigna and Express Scripts rolled out a program in which participating customers will pay no more than $25 for a 30-day insulin supply.

The legislation’s passage was cheered by diabetes and disability advocates, including the American Diabetes Association.

The Colorado BioScience Association, CVS Health, United HealthCare, and Pharmaceutical Research and Manufacturers of America (PhRMA) all opposed the legislation, according to a regional policy report. Reasons to impose the measure included that it has the potential to drive up insurance plan costs and that it is being administered by the Colorado Department of Law, rather than state insurance or health care policy regulators.

This appears to be the first state law aimed specifically at capping insulin out-of-pocket costs. Many other states are considering bills aimed at reducing the economic burden of the insulin pricing crisis, according to a Healthline report.

You can read the final text of the new law here.

 

Does Your Teen Have Eczema?

Eczema clinical study image of teenIf your child is between the ages of 12 – 17 and struggles with eczema (atopic dermatitis), you may be interested in a new research study in your local area. The study is for an investigational topical cream, applied twice daily for mild to moderate eczema.

The study lasts about 14 months, and there is no cost to participate. You will also be compensated for your time and travel to attend study visits.

To learn more, please call Metabolic Research Institute Inc. (561) 802-3060 or visit: https://www.metabolic-institute.com/eczema-study/


ABOUT METABOLIC RESEARCH INSTITUTE

Metabolic Research Institute, Inc. (“MRI”), is a private Clinical Research Company located at 1515 North Flagler Drive, Suite 440, West Palm Beach Florida 33401. Unless otherwise noted, all study-related appointments for qualified clinical participants in any MRI research trial will take place at this address.

Metabolic Research Institute’s clinical trials are designed to add to medical knowledge related to the treatment, diagnosis, and prevention of diseases or conditions, whether it’s diabetes, high blood pressure, heart disease, high cholesterol, or a variety of other health issues.

Type 1 Diabetes Clinical Trial

DO YOU HAVE TYPE 1 DIABETES?

CURRENTLY USING AN INSULIN PUMP? CONSIDER THE PRONTO-Pump-2 STUDY

Type 1 Diabetes Clinical Study FLyer imageYou may be eligible for a clinical research study that will test if an investigational ‘ultra-rapid’ insulin can offer better blood glucose control for people with type 1 diabetes who use an insulin pump than currently available rapid-acting insulins.

If you meet the study criteria you will need to attend regular study visits and will receive all study-related visits, lab tests, assessments, as well as study insulins and supplies at no cost. Travel reimbursement will also be available.

We are looking for participants who:
• Are at least 18 years old
• Are diagnosed with type 1 diabetes and have been using insulin continuously for at least 12 months
• Have been using an insulin pump with rapid-acting insulin for at least 6 months
• Have been using the MiniMed 530G (US), Paradigm Revel (US), MiniMed 630G (US and Canada), MiniMed 640G or Paradigm Veo (outside of the US and Canada) insulin pump for at least the past 90 days

For more information, call Metabolic Research Institute (561) 802-3060 or visit: https://www.metabolic-institute.com/csii/